Abstract
The complexation of terfenadine (Terf) with β-cyclodextrin (β-CD) in solution and solid state has been investigated by phase solubility diagram (PSD), differential scanning calorimetry (DSC), powder X-ray diffractometry (PXD) and proton nuclear magnetic resonance (1H-NMR). The PSD results indicated that the salt saturation with the buffer counter ion (citrate−2, H2PO −14 and Cl−1 ions) of Terf (pK a = 9.5) and the hydrophobic effect play in tandem to increase the value of the complex formation constant (K11) measured at different conditions of pH, ionic strength, buffer type and buffer concentration. The correlation of the free energy of complex formation (ΔG11) with the free energy of inherent solubility of Terf (ΔGSo) obtained by changing the pH, ionic strength and buffer concentration was used to measure the contribution of the hydrophobic effect (desolvation) to complex formation. The hydrophobic effect was found to constitute 57.8% of the driving force for complex stability, while other factors including specific interactions contribute −13.4 kJ/mol. 1H-NMR spectra of Terf–citrate and Terf–HCl salts gave identical chemical shift displacements (ΔΔ) upon complexation, thus indicating that the counter anions are positioned somewhere outside of the β-CD cavity. DSC, XRPD and 1H-NMR proved the formation of solid Terf/acid/β-CD ternary complexes.
Similar content being viewed by others
References
Loftsson T., Brewster E.M. (1996) J. Pharm. Sci. 85: 1017
Stella V.J., Rajewski R.A. (1997) Pharm. Res. 14: 556
L. Szente, J. Szejtli, M. Vikmon, J. Szeman, E. Fenyvesi, M.␣Pasini, E. Redenti, and P. Ventura: Proceedings of the 1st World Meeting on Pharm. Biopharm. Pharm. Tech., Chatenary Malabry, France: APGI, p. 579 (1995)
Redenti E., Szente L., Szejtli J. (2000) J. Pharm. Sci. 89: 1
P. Ventura, P. Chiesi, M. Pasini, E. Redenti, J. Szejtli, and M.␣Vikmon: US Patent 5855916. Chiesi Farmaceutici S.P.A. Co., Italy (1995)
A.A. Badwan, A. Abu-Malooh, M. Haddadin, and H. Ibrahim: US Patent 5646131. Arab company for Drug Industries and Medical appliances (ACDIMA), Jordan (1997)
Rekharsky M.V., Goldberg R.N., Schwarz F.P., Tewari Y.B., Ross P.D., Yamashoji Y., Inoue Y. (1995) J. Am. Chem. Soc. 117: 8830
Backensfeld T., Müller B.W., Kolter K., (1991) Int. J. Pharm. 74: 85
Müller B.W., Albers E. (1992) Int. J. Pharm. 79: 273
Esclusa-Diaz M.T., Gayo-Otero M., Perez-Marcos M.B., Vila-Jato J.L., Torres-Labandeira J.J. (1996) Int. J. Pharm. 142: 183
Kim Y., Oksanen D.A., Massefski W., Blake J.F., Duffy E.M., Chrunyk B., (1998) J. Pharm. Sci. 87: 1560
T. Higuchi, and K.A. Connors: In C.N. Reilley (ed.), Adv. Anal. Chem. Instrum. Wiley-Interscience, New York (1965), pp. 117–212
Zughul M.B., Badwan A.A., (1997) Int. J. Pharm. 151: 109
Al Omari M.M., Zughul M.B., Badwan A.A., Davies J.E.D. (2006) J. Incl. Phenom. 55: 247
British Pharmacopoeia, British Pharmacopoeia Commission. Market Towers: London; Addendum 1995, (1993)pp. 1613–1614
Astralian National Drug Information Service (1986) Astu. J. Pharm. 67: 1077
Lacerda A.E., Roy M.-L., Lewis E.W., Rampe D. (1997) Mol. Pharmacol. 52: 314
Fenyvesi E., Vikmon M., Szeman J., Redenti E., Delcanale M., Ventura P., Szejtli J. (1999) J. Incl. Phenom. 33: 339
Liu L., Guo Q.-X. (2002) J. Incl. Phenom. 42: 1
Al Omari M.M., Zughul M.B., Davies J.E.D., Badwan A.A. (2006) J. Pharm. Biomed. Anal. 41: 857
El-Barghouthi M.I., Masoud N.A., Al-Kafawein J.K., Zughul M.B., Badwan A.A. (2005) J. Incl. Phenom. 53: 15
Bacchi A., Pelizzi G., Sheldrick G.M., Amari G., Delcanale M., Redenti E. (2002) Supramol. Chem. 14: 67
Tong W., Lach J.L., Chin T., Guillory J.K. (1991) Pharm. Res. 8: 951
Tong W., Lach J.L., Chin T., Guillory J.K. (1991) J. Pharm. Biomed. Anal. 9: 1139
Choi H., Lee B., Han J., Lee M., Park K., Yong C., Rhee J., Kim Y., Kim C. (2001) Drug Dev. Ind. Pharm. 27: 857
Redenti E., Pasini M., Ventura P., Spisni A., Vikmon M. (1993) J. Incl. Phenom. 15: 293
Redenti E., Ventura P., Fronza G., Selva A., Rivara S., Vincenzo P., Mor M. (1999) J. Pharm. Sci. 88: 599
Faucci M.T., Melani F., Mura P. (2000) J. Pharm. Biomed. Anal. 23: 25
Acknowledgements
The authors are grateful to Dr. Tom Huckerby from Lancaster University (UK) for conducting 1H-NMR and for technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Al Omari, M.M., Zughul, M.B., Davies, J.E.D. et al. Effect of Buffer Species on the Complexation of Basic Drug Terfenadine with β-Cyclodextrin. J Incl Phenom Macrocycl Chem 58, 227–235 (2007). https://doi.org/10.1007/s10847-006-9147-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10847-006-9147-5